Small molecule-based therapy for Visceral pain: TWIST1 decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 15/February/2015, 21.27

Small molecule-based therapy for Visceral pain: TWIST1 decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 15/February/2015, 21.27

Small molecule-based therapy for Visceral pain: TWIST1 decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 15/February/2015, 21.27 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, Small molecule-based therapy for Visceral pain: TWIST1 decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 15/February/2015, 21.27, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that TWIST1, by increasing the expression of its target gene, it may decrease visceral pain in patients with Irritable Bowel Syndrome.  Thus, pharmacological formulations encompassing “TWIST1 activators“  may be used to treat visceral pain.

Amount: $ 500*

Undisclosed information: How  TWIST1 decreases visceral pain

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Share
Start Typing